Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin. WMJ 2016 Aug;115(4):206-9

Date

08/01/2016

Pubmed ID

29099159

Scopus ID

2-s2.0-85036614235 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

OBJECTIVE: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes.

METHODS: We describe a case in which a patient experienced difficult-to-treat metabolic ketoacidosis in the setting of canagliflozin use.

RESULTS: A 52-year-old man with type 2 diabetes mellitus developed profound ketoacidosis without overt hyperglycemia while taking canagliflozin. Despite initiation of an insulin infusion, the metabolic acidosis persisted for 3 days.

CONCLUSION: Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.

Author List

Danford C, Chan P, Magill SB

Author

Steven B. Magill MD, PhD Staff Physician in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Blood Glucose
Canagliflozin
Diabetes Mellitus, Type 2
Humans
Hypoglycemic Agents
Ketosis
Male
Middle Aged